The rising interest in successful weight management has spurred considerable investigation into novel treatments. Currently, Retatrutide, a dual -action hormone and glucagon-like peptide-1 (GLP-1) receptor agonist , has shown encouraging results in clinical trials, suggesting potential for considerable weight decrease. Therefore, many individuals a